FreshLeaf Analytics News

Australian Senate Committee tables recommendations from inquiry into barriers to medical cannabis The Community Affairs and References Committee tabled their report today (25/3/20) on the inquiry into barriers to medical cannabis patient access in Australia.  FreshLeaf has covered this inquiry extensively and attended the public hearings, so if you’re interested in the recent history of...Read More

What does a global recession mean for the cannabis industry? COVID-19 is wreaking havoc on the global economy. And there are genuine concerns about a prolonged economic downturn, unlike any other in recent memory. People are worried about their health and for their families, as well as their businesses and jobs. The performance and survival...Read More

Medical cannabis quality crack-down   The Therapeutic Goods Administration (TGA) has announced it will be ramping up the number of quality audits it conducts on imported medical cannabis products. This will include analytical testing to assess compliance with TGO93, the quality standard for cannabis products.  TGO93 requires products to have acceptable levels of pesticides, heavy...Read More

We attended the ODC’s consultation session on proposed medical cannabis license changes so you didn’t have to The Office of Drug Control (ODC) held consultation sessions in three capital cities over the last week seeking feedback on their proposed changes to Australia’s commercial medical cannabis licensing system. FreshLeaf attended the Sydney workshop on February 3rd...Read More

The TGA is re-examining the clinical evidence for medical cannabis – including over-the-counter CBD This is the third article in our series about the Department of Health’s submission to the Senate Inquiry into medical cannabis patient access. You can read the Department’s submission here. In December 2017 the TGA, in collaboration with several universities, produced...Read More

Department of Health releases new medical cannabis patient access info The TGA tends to avoid speaking about prescriptions because they have no direct oversight regarding scripts. Instead they focus on SAS-A/B approvals and AP notifications. These can be considered proxy figures for access. And if you have empirical data about prescriptions per approval, and empirical...Read More

Department of Health provides new commercial insights to Senate Inquiry The Senate Inquiry into the current barriers to patient access to medicinal cannabis in Australia has already revealed some fascinating new pieces of information on the performance of our medical cannabis framework. Public submissions to the Inquiry are available on the APH website and they...Read More

FreshLeaf’s top ten 2020 trends for Australia’s medical cannabis industry You don’t need a crystal ball to know that 2020 is going to be a big year for cannabis in Australia and around the world. But what does that mean exactly for companies, patients and regulators? Here are the top 10 most important trends in...Read More